Testing safety of AZD1613 for polycystic kidney disease
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney disease called ADPKD (autosomal dominant polycystic kidney disease), with a specific pattern of cyst growth (Mayo class 1B to 1E).
- Your kidney function (eGFR) is between 45 and 90 mL/min, meaning your kidneys still work pretty well.
- You weigh at least 45 kg (about 100 pounds) and your body mass index is between 18 and 35.
- If you are female, you must not be able to become pregnant (for example, after menopause or surgery).
- You do not have certain heart problems, such as long QT syndrome or uncontrolled heart rhythm issues.
- You have not had any kidney cyst draining procedures in the last 12 weeks, and none are planned.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
This study looks at how the body’s “Nrf2 response” works in people with autosomal dominant polycystic kidney disease (ADPKD). It may help researchers better understand disease biology and future treatments by comparing kidney-related signals in ADPKD patients and healthy volunteers.
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This study is for healthy volunteers to see how a new experimental drug (JMKX003142) interacts with other drugs in the body. It helps find the right dose for future patients.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
Hear when a new Autosomal Dominant Polycystic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.